Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

8.64  +0.01 (+0.12%)

Premarket: 8.6501 +0.01 (+0.12%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALVO. ALVO was compared to 556 industry peers in the Biotechnology industry. ALVO has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALVO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year ALVO has reported negative net income.
ALVO had a negative operating cash flow in the past year.
ALVO had negative earnings in each of the past 5 years.
In the past 5 years ALVO always reported negative operating cash flow.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.75%, ALVO belongs to the top of the industry, outperforming 93.88% of the companies in the same industry.
The Return On Invested Capital of ALVO (10.37%) is better than 95.50% of its industry peers.
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROIC 10.37%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Profit Margin, with a value of 16.42%, ALVO belongs to the top of the industry, outperforming 94.60% of the companies in the same industry.
ALVO's Operating Margin of 21.88% is amongst the best of the industry. ALVO outperforms 96.04% of its industry peers.
The Gross Margin of ALVO (60.74%) is better than 79.14% of its industry peers.
Industry RankSector Rank
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALVO is still creating some value.
The number of shares outstanding for ALVO has been increased compared to 1 year ago.
The debt/assets ratio for ALVO has been reduced compared to a year ago.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ALVO has an Altman-Z score of 0.43. This is a bad value and indicates that ALVO is not financially healthy and even has some risk of bankruptcy.
ALVO has a Altman-Z score of 0.43. This is in the better half of the industry: ALVO outperforms 64.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.43
ROIC/WACC1.47
WACC7.04%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ALVO has a Current Ratio of 1.73. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
ALVO has a Current ratio of 1.73. This is in the lower half of the industry: ALVO underperforms 79.32% of its industry peers.
ALVO has a Quick Ratio of 1.19. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.19, ALVO is not doing good in the industry: 84.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.19
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

7

3. Growth

3.1 Past

ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.39%, which is quite impressive.
The Revenue has grown by 426.84% in the past year. This is a very strong growth!
Measured over the past years, ALVO shows a very strong growth in Revenue. The Revenue has been growing by 42.86% on average per year.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

ALVO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.57% yearly.
ALVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.63% yearly.
EPS Next Y111.33%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue Next Year44.54%
Revenue Next 2Y43.57%
Revenue Next 3Y41.63%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 17.47, ALVO is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ALVO is valued cheaply inside the industry as 93.53% of the companies are valued more expensively.
ALVO is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 17.47
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

92.27% of the companies in the same industry are more expensive than ALVO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 39.95
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

ALVO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVO's earnings are expected to grow with 46.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.27%
EPS Next 3Y46.57%

0

5. Dividend

5.1 Amount

No dividends for ALVO!.
Industry RankSector Rank
Dividend Yield N/A

ALVOTECH SA

NASDAQ:ALVO (7/21/2025, 8:00:00 PM)

Premarket: 8.6501 +0.01 (+0.12%)

8.64

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-13 2025-08-13/amc
Inst Owners6%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap5.24B
Analysts78
Price Target18.26 (111.34%)
Short Float %1.62%
Short Ratio7.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)225.45%
Min EPS beat(2)38.96%
Max EPS beat(2)411.94%
EPS beat(4)4
Avg EPS beat(4)2391.55%
Min EPS beat(4)38.96%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)33.69%
Min Revenue beat(2)30.36%
Max Revenue beat(2)37.03%
Revenue beat(4)3
Avg Revenue beat(4)19.69%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)37.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.56%
PT rev (3m)-3.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)341.68%
EPS NY rev (3m)157.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.05%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)1.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.47
P/S 8.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 39.95
EPS(TTM)-0.87
EYN/A
EPS(NY)0.49
Fwd EY5.73%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.97
BVpS-0.5
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.75%
ROE N/A
ROCE 13.13%
ROIC 10.37%
ROICexc 10.8%
ROICexgc 11.19%
OM 21.88%
PM (TTM) 16.42%
GM 60.74%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 7.35
Cap/Depr 234.04%
Cap/Sales 12.89%
Interest Coverage 2.32
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.19
Altman-Z 0.43
F-Score6
WACC7.04%
ROIC/WACC1.47
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y111.33%
EPS Next 2Y60.27%
EPS Next 3Y46.57%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year44.54%
Revenue Next 2Y43.57%
Revenue Next 3Y41.63%
Revenue Next 5YN/A
EBIT growth 1Y141.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year175.98%
EBIT Next 3Y87.82%
EBIT Next 5YN/A
FCF growth 1Y45.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.75%
OCF growth 3YN/A
OCF growth 5YN/A